A. Clinical trials dose toxicity curves | |||||
Dose escalation method | MTD selected by dose-escalation method (%) | ||||
True selected | Underestimated | Overestimated | < lowest dose | ||
3 + 3 | 65.2 | 31.8 | 2.3 | 0.7 | |
Extended CRM | Step-up | 76.7 | 9.0 | 13.9 | 0.4 |
Dose-Linear | 76.7 | 4.2 | 21.5 | 0.4 | |
O’Quigley | 76.6 | 11.6 | 14.4 | 0.4 | |
Conservative | 74.8 | 16.6 | 8.2 | 0.4 | |
Sigmoidal | 73.8 | 14.7 | 8.3 | 0.4 | |
Aggressive | 68.5 | 6.7 | 24.4 | 0.4 | |
B. Theoretical dose toxicity curves | |||||
Dose escalation method | MTD selected by dose-escalation method (%) | ||||
True selected | Underestimated | Overestimated | < lowest dose | ||
3 + 3 | 34.8 | 42.6 | 7.3 | 15.3 | |
Extended CRM | Conservative | 52.9 | 21.6 | 20.7 | 4.9 |
Sigmoidal | 46.4 | 19.1 | 29.9 | 4.6 | |
Step-up | 42.8 | 22.1 | 30.1 | 5.1 | |
O’Quigley | 40.6 | 21.4 | 32.9 | 5.1 | |
Aggressive | 39.4 | 21.3 | 34.5 | 4.9 | |
Dose-Linear | 37.2 | 18.3 | 40.4 | 4.1 | |
C. All dose toxicity curves | |||||
Dose escalation method | MTD selected by dose-escalation method (%) | ||||
True selected | Underestimated | Overestimated | < lowest dose | ||
3 + 3 | 50.0 | 37.2 | 4.8 | 8.0 | |
Extended CRM | Conservative | 63.9 | 19.1 | 14.4 | 2.6 |
Sigmoidal | 61.5 | 16.9 | 19.1 | 2.5 | |
Step-up | 59.7 | 15.5 | 22.0 | 2.8 | |
O’Quigley | 57.1 | 16.5 | 23.6 | 2.7 | |
Dose-Linear | 55.5 | 11.3 | 31.0 | 2.2 | |
Aggressive | 53.9 | 14.0 | 29.4 | 2.6 |